| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 15, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2025 | $46.00 | Mkt Outperform | Citizens JMP |
| 1/27/2025 | Overweight | Cantor Fitzgerald | |
| 12/13/2024 | $34.00 | Outperform | RBC Capital Mkts |
| 11/8/2024 | $33.00 | Buy | Guggenheim |
| 8/14/2024 | $24.00 | Neutral → Buy | H.C. Wainwright |
| 12/3/2021 | $6.00 | Buy | H.C. Wainwright |
| 9/22/2021 | $9.00 → $8.00 | Buy | Aegis Capital |
| 9/22/2021 | $6.25 | Buy → Strong Buy | WBB Securities |
SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, click here. The event will feature key opinion leaders (KOLs) Fred Hayden, MD, FACP (University of Virginia School of Medicine) and Rick Bright, PhD (Pandemic Prevention Institute, The Rockefeller Foundation), who will join company management to discuss CD388, Cidara's long-acting antiviral drug designed to revolutionize influenza pro
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences. Event: RBC Global Healthcare ConferenceDate: Wednesday, May 21, 2025Time: 10:00 AM ET Event: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:40 AM ET The live webcast for the presentations can be accessed in the Investors section on the Company's website at https://www.cidara.com/investors/events/. Replays of the presentations will be available for at least 30 days. Cida
Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and pro
Citizens JMP initiated coverage of Cidara Therapeutics with a rating of Mkt Outperform and set a new price target of $46.00
Cantor Fitzgerald resumed coverage of Cidara Therapeutics with a rating of Overweight
RBC Capital Mkts initiated coverage of Cidara Therapeutics with a rating of Outperform and set a new price target of $34.00
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
3 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and pro
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, May 8, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Thursday, May 8, 2025Time:5:00 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Conferen
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the com
Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Frank Karbe, MBA, has been appointed Chief Financial Officer (CFO), effective February 24, 2025. Mr. Karbe will succeed Preetam Shah, Ph.D., MBA, who is departing to pursue other professional opportunities. Dr. Shah will serve as a consultant to the Company. "We are pleased to welcome Frank to the team as we advance our long-acting influenza antiviral drug CD388 through the e
EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)
SCHEDULE 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)
SCHEDULE 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)